NL-OMON25484Other不适用
Towards a novel immune therapy platform with an innate allogeneic haematopoietic stem cell transplantation in patients with haematological malignancies
MC UtrechtHeidelberglaan 1003584 CX Utrecht0 个研究点目标入组 35 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- Other
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Haematological malignancies eligible to allo-SCT
排除标准
- •Relapse of allo-SCT within 6 months after allo-SCT
- •Bilirubin and/or transaminases > 2.5 x normal value
研究者
相似试验
招募中
不适用
Development of new approaches for immunotherapy of non-small cell lung cancerC34Malignant neoplasm of bronchus and lungDRKS00029641Molekulare PneumologieUniversitätsklinikum Erlangen
招募中
2 期
An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS studyBlood - Haematological diseasesMultiple MyelomaACTRN12621001037897Australasian Myeloma Research Consortium50
已完成
不适用
An immune therapy register for the improvement of drug safety and treatment of patients with Multiple SclerosisMultiple sclerosisG35DRKS00007190Bundesministerium für Bildung und Forschung Dienstsitz Bonn1,886
尚未招募
Unknown
To find Natural killers cells as a treatment option for Triple negative breast cancer.CTRI/2023/10/058292Tata Memorial Center
已完成
不适用
Development of a personalized immune-modulating therapy for patients with atopic dermatitis: evaluation of clinical efficacy of autologous immunoglobulin therapy for atopic dermatitis: a randomized, double-blind, placebo-controlled studyDiseases of the skin and subcutaneous tissueKCT0001597Ajou University Hospital51